Participated · Series B · Sep 2025

Cyted Health offers a diagnostics platform built around EndoSign®, an FDA 510(k)-cleared device for minimally invasive collection of esophageal cells combined with advanced biomarker molecular testing. The company has completed over 35,000 tests across the UK’s National Health Service and has a portfolio of peer-reviewed publications demonstrating patient acceptability and clinical impact. Cyted was founded by experts at the University of Cambridge and is developing additional advanced diagnostic tests for pre-cancerous, cancerous, and inflammatory esophageal conditions. Management has expanded a Clinical Advisory Board of gastroenterology and oncology leaders to guide product development and clinical strategy. Near-term plans focus on consolidating commercial success in the UK, expanding the diagnostics portfolio, and accelerating commercial expansion in the US. Cyted was founded in 2020 by Professor Rebecca Fitzgerald OBE and Dr Marcel Gehrung and is based in Cambridge. Its diagnostic platform pairs a non-invasive test with data-driven biomarkers to enable earlier detection and risk stratification of cancers and inflammatory diseases, with an initial application in oesophageal cancer. The company's primary aim is to provide early-detection tests for oesophageal cancer to NHS patients in primary and community care settings. Cyted has delivered over 15,000 tests across more than 80 UK sites and has been rolling out community and primary-care testing since August 2022. It plans to use new funding to expand operations in existing markets, enter the US market, and further develop R&D programmes focused on gastrointestinal cancers and diseases. The recent financing and public-sector grants underline clinical traction and support for wider NHS deployment.

Led · Equity · Apr 2023

Augmedix delivers AI-powered ambient medical documentation and data solutions that convert natural clinician–patient conversations into medical notes clinicians can review, finalize, and transfer in real time to the electronic health record. Its technology targets both ambulatory care and, through a new collaboration, the acute care setting. The company plans to work with HCA Healthcare to advance AI-powered ambient documentation products for acute care clinicians and to accelerate development of products such as Augmedix Go. Augmedix raised approximately $12 million in new equity from HCA Healthcare and Redmile Group via a combination of new common shares and pre-funded warrants priced at $1.60 per share. The financing also included issuance of conditional “break even” warrants tied to specific future financing events. Management says the new capital, together with existing cash and availability under an existing debt facility, should enable the company to reach cash flow sustainability and avoid additional equity raises, with breakeven expected as it exits 2024. The company and Redmile have also agreed to finalize within 30 days an equity line option of up to $5 million at $1.60 per share that could be accessed 12–18 months after finalization, although management does not anticipate using it. Augmedix provides remote medical documentation and live clinical support, converting natural clinician–patient conversation into medical documentation using proprietary automation modules and human-expert assistants operating in HIPAA-secure locations. Its platform supports over 35 specialties and is used by more than one dozen American health systems and hundreds of independent clinicians across medical offices, clinics, hospitals and telemedicine. The company estimates its solution saves clinicians 2–3 hours per day, can increase productivity by as much as 20%, and improves clinicians' satisfaction with work-life balance by over 40%. Augmedix completed a fourth quarter 2020 capital raise and achieved an OTCQX listing, and management cites strong financial performance. In March 2021 the company refinanced its long-term debt to enhance the balance sheet and significantly extend operating runway. Proceeds from the refinancing were used to pay down existing long-term debt and for working capital and general corporate purposes. Augmedix offers a platform that converts natural clinician–patient conversation into medical documentation and delivers live clinical support such as referrals, orders, and reminders. Its platform combines proprietary automation modules with human-expert assistants operating in HIPAA-secure locations to produce accurate, comprehensive, and timely documentation. Augmedix says its services are compatible with over 35 specialties and are trusted by more than one dozen U.S. health systems across telemedicine, clinics, and hospitals. The company estimates its solution saves clinicians 2–3 hours per day, can increase productivity by as much as 20%, and improve certain clinicians' work‑life balance by 49%. Management said the COVID‑19 pandemic has accelerated telemedicine adoption and highlighted Augmedix’s competitive advantages. The company plans to broaden operational capabilities, accelerate technology research and product development, and strengthen marketing and sales following the financing. Augmedix provides real‑time medical documentation by turning natural clinician–patient conversation into notes via a platform powered by proprietary natural‑language‑processing technology and medical documentation expert teams. The company supplies clinicians with hardware (Smartphones or Google Glass) to securely stream visits to its cloud‑based platform, where tech‑enabled remote specialists and proprietary automation modules generate comprehensive documentation. Its service covers more than 25 specialties and supports most EHRs. Fifteen national health systems, including Sutter Health, CommonSpirit Health, and US Oncology, representing over 10% of clinicians in the U.S., have partnered with Augmedix. The company is led by CEO Manny Krakaris. It raised an additional $19M in Series B financing to accelerate product development, including automation capabilities, and to scale its technology‑enabled service across health systems and private clinics nationwide. Augmedix offers a Google Glass-powered remote scribe service that lets physicians retrieve patient history and document visits without interacting with a computer; chart notes are created in real time by remote scribes in secure HIPAA-compliant facilities. The service enables physicians to review notes and provide patients with visit summaries and care instructions. Augmedix complements its core offering with enterprise support services including staffing, quality assurance, network and technical support, analytics and business process improvement. The company has received more than $60 million in venture funding since founding. It intends to use the new funds to further scale its service nationwide and build out its platform with new tools and services.

Participated · Series D · Apr 2022

Viz.ai operates an AI-powered platform that identifies patients, informs critical decisions at the point of care, and coordinates radiologists, emergency physicians and specialists to optimize care pathways. The platform is backed by clinical evidence and is used to increase speed of diagnosis and access to life-saving treatments. Viz.ai serves a patient every 21 seconds and covers more than 220 million lives across 1,300+ hospitals and health systems in the U.S. and Europe. The company plans to expand its end-to-end platform into new disease areas and evaluate strategic acquisition opportunities. Viz.ai recently received growth capital financing to support that expansion and continued product development. The business is supported by a roster of venture investors that have previously backed the company. Viz.ai provides an AI-driven platform that delivers synchronized care coordination, high-fidelity mobile image viewing, automated workflows, and computational diagnostics to connect radiologists, emergency physicians, and primary care practitioners with specialists. The company pioneered stroke detection and triage with a de novo FDA clearance and was the first AI software to receive CMS NTAP approval. Viz.ai has expanded its platform into additional disease states (aortic disease, pulmonary embolism, cerebral aneurysms) and is 510(k) pending for subdural hematoma, and it launched a life-science platform to support clinical trials. The Viz Platform is used in more than 1,000 hospitals across the US and EMEA, has assisted millions of patients, and the company says it assists in the care of one patient every 32 seconds. The business is growing rapidly: headcount rose from 180 to more than 350 over the past 12 months and the company plans to hire nearly 200 more in the next 12 months. Viz.ai lists customers including Mount Sinai, Thomas Jefferson University, Banner Health, CommonSpirit Health, and HCA Healthcare, and operates from offices in San Francisco, Tel Aviv, Portugal, and Amsterdam. Viz.ai’s core product is an AI-powered Intelligent Care Coordination platform, with flagship offering Viz LVO that detects large vessel occlusions and routes time-sensitive information to specialists. The platform includes automated alerts and triage, mobile DICOM image viewing, HIPAA-compliant messaging, and point-of-care consults. Viz LVO has multiple FDA clearances (De Novo in 2018; additional clearances for Viz CTP and Viz ICH) and received the first CMS NTAP for AI software; a multi-center real-world study reported a median time-to-notification of 5 minutes 45 seconds and achieved 96% sensitivity and 94% specificity across 2,544 consecutive patients from 139 hospitals. The company plans to expand the platform beyond stroke into other acute care specialties such as cardiology, pulmonary and trauma, and to enter new global markets. Viz.ai says its technology improves triage, patient outcomes, and economics for health systems by reducing time to treatment and preventing care breakdowns. The company is based in San Francisco and Tel Aviv and positions its product as clinically validated and commercially reimbursed in relevant cases. Viz.ai builds synchronized healthcare software (Viz) that leverages deep learning to identify suspected large vessel occlusions (LVO) on CT scans and notify stroke specialists to speed treatment. Its flagship product, Viz LVO, routes time-sensitive information to clinicians in minutes to synchronize care and reduce time to treatment. In February 2018 the FDA granted De Novo clearance for Viz LVO; the company later received 510(k) clearance for Viz CTP for automated cerebral perfusion analysis. Viz.ai’s acute ischemic stroke software is deployed in over 300 U.S. hospitals and is credited with shortening time to treatment and increasing the number of patients able to receive lifesaving therapy. Management says the company will use the new funding to expand Synchronized Care to additional disease states and geographies to democratize quality of care globally. The company positions its platform to curate expanding healthcare data and make it immediately actionable for providers, aiming to reduce costs and support value-based care. Viz.ai develops a cloud-based AI platform that analyzes brain CT scans to detect large vessel occlusions and alerts neurovascular specialists to speed treatment. Its flagship product, Viz LVO, was granted FDA De Novo clearance and the company also received FDA 510(k) clearance for Viz CTP. The platform uses deep learning to automate triage and is designed to integrate with existing emergency-room workflows. Viz.ai says the software delivers alerts in minutes to facilitate early therapeutic intervention and improve access to proven therapies. The company will use the $21 million Series A to expand market reach and to extend its product portfolio beyond stroke. Founded in 2016 and based in San Francisco and Tel Aviv, Viz.ai is backed by Kleiner Perkins, GV, Innovation Endeavors and DHVC.

Participated · Equity · Mar 2018

Digital Reasoning is a leader in artificial intelligence that understands human intentions and behaviors and provides communications analytics. Its AI platform automates tasks and uncovers insights across vast amounts of human communications for financial services and healthcare organizations. The company focuses on e-communications and voice surveillance for compliance, identifying risks and insights from language and behavior. Through a partnership with SC Ventures/Standard Chartered, Digital Reasoning plans to expand its communications surveillance offerings across Asia Pacific, the Middle East, and Africa. The investment will also support broadening its pre-trained model catalog to support growth in those financial markets. Digital Reasoning's Series D-1 funding round has reached a $40 million total. Digital Reasoning operates an AI platform focused on Language Process Automation (LPA) and Human Behavioral Insights (HBI). Its technology automates key tasks and uncovers insights across large volumes of human communications data for organizations and government agencies. The company completed a $30m Series D-1 funding round in March 2018 and has since received a strategic investment from Macquarie Group; the amount of the latest deal was not disclosed. As part of the investment, Digital Reasoning will partner with Macquarie to explore new financial‑services use cases for its platform. Macquarie’s global presence is expected to accelerate the company’s expansion into Australia and Asia. No operating metrics or additional financial details were disclosed in the article. Digital Reasoning provides AI-powered solutions that use patented technology to turn all forms of communications data, including audio and voice, into discoverable, understandable, and actionable insights for large enterprises. The company focuses on customer-centric data strategies and targets use cases in capital markets and wealth management. Led by CEO Brett Jackson and president and founder Tim Estes, Digital Reasoning combines speech analytics, natural language understanding and machine education in its product set. It raised $30M in funding to support its growth. Angel Rodriguez-Issa of BNP Paribas joined the company’s board as part of the round. The firm plans to use the proceeds to expand its product portfolio, accelerate AI innovations across speech analytics, NLU and machine education, and expand go-to-market capacity. Digital Reasoning builds a cognitive computing platform and intelligent assistants aimed at helping organizations with surveillance, compliance, and healthcare analytics. The company emphasizes applying state-of-the-art deep learning across its offerings to enhance customer outcomes and support data scientists and knowledge workers. It is pursuing partnerships to deliver holistic surveillance solutions and to surface insights from electronic health records to improve clinical care. The company plans to expand its team to pursue life‑saving analytics in health care with partners such as HCA and to drive novel data science initiatives at large enterprises. Recent governance changes include the addition of investor representatives to the board to support product and commercial expansion. Digital Reasoning is a cognitive computing company that develops the Synthesys® platform to unlock insights in unstructured patient and clinical records. The company is positioning Synthesys® to pair with existing Electronic Medical Records and Clinical Data Warehouses to surface clinically relevant insights. Leadership highlights in the release include CEO Tim Estes, Board Chairman Dr. Jack Lord, and CTO Matthew Russell; HCA’s Dr. Jonathan B. Perlin joined the board. Digital Reasoning says it is expanding from prior work in government and financial services into health care with a long-term commitment to providers and payers. The stated aim is to deliver an ecosystem of intelligent applications that improve clinical workflows, patient care, clinical outcomes, and operational efficiencies.

Participated · Equity · Aug 2013

InVivoLink is a Nashville, Tenn.-based maker of web-based mobile apps and software that helps healthcare providers and manufacturers track performance measures. Its product centers on an evidence-based medicine web portal that lets surgeons, sales reps and nurses input data to streamline workflow. The company is focused on an orthopedic application that aims to produce a dynamic "report card" summarizing an entire episode of care, including patient outcomes, surgical notes and emailed communications. InVivoLink raised $1.9 million in an equity financing described as the second wave of an initial funding promise. The company plans to use the proceeds to hire new staff and continue development of the orthopedic application. CEO Ryan Wells said the tranche will kick in after the company achieves certain milestones.